| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825970 | Current Opinion in Pharmacology | 2015 | 7 Pages |
Abstract
Macrophage infiltration has been identified as an independent poor prognostic factor for several cancer entities. In mouse tumor models macrophages orchestrate various tumor-promoting processes. This observation sparked an interest to therapeutically target these plastic innate immune cells. To date, blockade of colony stimulating factor-1 or its receptor represents the only truly selective approach to manipulate macrophages in cancer patients. Here, we discuss the currently available information on efficacy and safety of various CSF-1/CSF-1R inhibitors in cancer patients and highlight potential combination partners emerging from preclinical studies while considering the differences between mouse and human macrophage biology.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Carola H Ries, Sabine Hoves, Michael A Cannarile, Dominik Rüttinger,